Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...
Scientists from the RIKEN Center for Emergent Matter Science and colleagues have developed a new way to fabricate ...
Researchers from New England Biolabs (NEB®) and Yale University describe the first fully synthetic bacteriophage engineering ...
Speeding up drug discovery in the age of AI may come down to a concept that's comfortingly old-fashioned: Consulting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results